Scholarlink

<p>Anti BCMA bispecific antibodies (BsAb) have changed the treatment landscape of relapsed-refractory multiple myeloma (RRMM). However, these drugs are associated with high rates of infections. This is a retrospective analysis of patients of RRMM who received either Elranatamab or Teclistamab from January, 2023 to September, 2025. The primary objective was to assess response rates, whereas the secondary objectives were to assess OS, PFS, haematological toxicities and non-hematological toxicities. Nine patients received Anti BCMA BsAb (four patients received Elranatamab and five patients received Teclistamab). Median age was 63 years (Range 30-67 years). 77.8% were males. Median prior lines received were five (Range: 3-8). Four patients (44.4%) achieved sCR, two patients (22.2%) achieved CR, 1 patient (11.1%) achieved VGPR and 2 patients (22.2%) had progressive disease (PD). Hypogammaglobulinemia was seen in eight (88%) patients. Nine patients had 23 episodes of infections. Nine grade III/IV infectious episodes were seen. CD3 x BCMA BsAb induces remission in RRMM but is also associated with profound immunosuppression and increased infections. Pre-emptive/prophylactic Immunoglobulin (Ig) replacement can mitigate the infection risk in these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real world data on Anti BCMA bispecific antibody therapy in relapsed refractory multiple myeloma - treading on a razor edge between efficacy and safety

  • 期刊论文

  • 发表日期：

    2026年3月24日

查看全文
  • Dibakar Podder,
  • Noopur Patil,
  • Shouriyo Ghosh,
  • Jeevan Kumar,
  • Sarthak Ghosh,
  • Soumyadip Chatterji,
  • Saswata Saha,
  • Bikash Shah,
  • Arijit Nag,
  • Debranjani Chattyopadhyay,
  • Rizwan Javed,
  • Ashish Rath,
  • Pampi Majumder,
  • Subhosmito Chakraborty,
  • Sanjay Bhattacharya,
  • Gaurav Goel,
  • Mayur Parihar,
  • Deepak Mishra,
  • Pralay Shankar Ghosh,
  • Reena Nair

摘要

Anti BCMA bispecific antibodies (BsAb) have changed the treatment landscape of relapsed-refractory multiple myeloma (RRMM). However, these drugs are associated with high rates of infections. This is a retrospective analysis of patients of RRMM who received either Elranatamab or Teclistamab from January, 2023 to September, 2025. The primary objective was to assess response rates, whereas the secondary objectives were to assess OS, PFS, haematological toxicities and non-hematological toxicities. Nine patients received Anti BCMA BsAb (four patients received Elranatamab and five patients received Teclistamab). Median age was 63 years (Range 30-67 years). 77.8% were males. Median prior lines received were five (Range: 3-8). Four patients (44.4%) achieved sCR, two patients (22.2%) achieved CR, 1 patient (11.1%) achieved VGPR and 2 patients (22.2%) had progressive disease (PD). Hypogammaglobulinemia was seen in eight (88%) patients. Nine patients had 23 episodes of infections. Nine grade III/IV infectious episodes were seen. CD3 x BCMA BsAb induces remission in RRMM but is also associated with profound immunosuppression and increased infections. Pre-emptive/prophylactic Immunoglobulin (Ig) replacement can mitigate the infection risk in these patients.